Main Street Group’s CRISPR Therapeutics CRSP Stock Holding History

Main Street Group’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.38K	Hold	62	–	–	﹤0.01%	696
2026 Q1	$2.95K	Buy	+62	New	+$3.27K	﹤0.01%	704
2025 Q4	–	Sell	-62	Closed	-$4.02K	–	201
2025 Q3	$4.02K	Hold	62	–	–	﹤0.01%	639
2025 Q2	$3.02K	Hold	62	–	–	﹤0.01%	626
2025 Q1	$2.11K	Hold	62	–	–	﹤0.01%	666
2024 Q4	$2.44K	Sell	62 -488	-89%	-$23K	﹤0.01%	643
2024 Q3	$25.8K	Hold	550	–	–	0.01%	355
2024 Q2	$29.7K	Hold	550	–	–	0.01%	340
2024 Q1	$37.5K	Hold	550	–	–	0.02%	323
2023 Q4	$34.4K	Buy	+550	New	+$30.4K	0.01%	485

Other funds holding CRSP

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

WETS

Wealth Enhancement Trust Services Sioux Falls, South Dakota $792M AUM

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BIP

Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

IIM

Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return

PFGIA

Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return

BAM

Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Main Street Group's CRSP Position: Q2 2026 in Review

Main Street Group held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 62 shares worth $3.38K. The position accounts for ﹤0.01% of the portfolio, ranked #696.

Main Street Group first reported a position in CRSP in Q4 2023 and has held it in 10 quarters since. The position peaked at $37.5K in Q1 2024. 62 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Main Street Group held 62 shares of CRISPR Therapeutics worth $3.38K as of Q2 2026.
Main Street Group left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Main Street Group's portfolio in Q2 2026, its #696 holding.
Main Street Group first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 10 quarters since.
Main Street Group's CRISPR Therapeutics position peaked at $37.5K in Q1 2024.
62 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Main Street Group's 13F filing for Q2 2026, filed 13 Jul 2026.